Developer docs
API playgroundTry for free, no card

Search company profiles

OrbiMed

Full company profile

uuid000002t

Namestring
OrbiMed
Legal namestring
OrbiMed Advisors LLC
Websiteurl
orbimed.com
Company typeenum
Private
Founded yearint
1989
Descriptiontext

OrbiMed Advisors LLC is a privately held, partner-led global healthcare investment firm founded in 1989 and headquartered in New York City. The firm manages approximately $20 billion in assets under management across 500+ portfolio companies and operates through three integrated strategies: Private Equity (seed to growth across biopharmaceuticals, medical devices, diagnostics, and healthcare services), Private Credit / Royalty (non-dilutive structured debt and royalty monetization for commercial-stage companies), and Public Equity (long/short event-driven funds and closed-end trusts across publicly traded healthcare companies). The firm invests globally from 12 offices spanning New York, San Francisco, Shanghai, Hong Kong, Herzliya, and London, with 150+ scientific, medical, and investment professionals executing lead-investor positions and providing board representation and follow-on capital.

The firm's core proprietary capability is a healthcare-only investment platform combining deep scientific expertise with disciplined due diligence, formalized in an ESG-aligned Responsible Investing Policy overseen by a Director–ESG. OrbiMed is ranked number one on the Endpoints News Top 100 biotech venture investors list and has backed 130+ venture-backed IPOs, 80+ developed therapies, and 110+ life sciences startups. Notable 2026 deployments include leads or co-leads in Windward Bio ($165M), Mirador Therapeutics ($250M), Odyssey Therapeutics ($310M), and the close of the $1.86B Healthcare Royalty & Credit Fund V.

OrbiMed generates revenue primarily through recurring management fees on AUM across its private equity, public equity, and private credit/royalty funds, supplemented by carried interest on successful exits and royalty/credit investment income. Capital is raised bilaterally from institutional limited partners and deployed through direct partner-led deal sourcing. Recent management includes CEO Donnie McGrath, founders Sam Isaly, Sven Borho, and Michael B. Sheffery, and managing partners Carl Gordon and W. Carter Neild.

Short descriptiontext

OrbiMed is a privately held, healthcare-only investment firm founded in 1989 managing approximately $20 billion in AUM across private equity, public equity, and royalty/credit strategies, serving life sciences and healthcare companies globally from 12 offices.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare investment management, private equity funds, biopharmaceutical venture capital, royalty financing, public equity investing
Product category
Healthcare Investment Management
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Management Fees on Funds under Management
TypeSubscription Recurring
Description

OrbiMed earns recurring management fees on the approximately $20 billion in assets under management across its multiple private equity, public equity, private credit/royalty, and royalty funds. This is a traditional asset-management revenue stream driven by AUM size.

orbimed.com
2Investment Returns (Carried Interest / Performance Fees)
TypeLicensing Royalties
Description

As a healthcare-focused investment firm investing across the capital structure (equity, credit, and hybrid instruments) from seed-stage start-ups to large multinational corporations, OrbiMed generates returns from realized and unrealized gains on its investments, including carried interest on successful exits. Notable successes include 130+ venture-backed IPOs from its portfolio.

orbimed.com
3Royalty Monetization & Structured Credit Income
TypeLicensing Royalties
Description

Through its Private Credit/Royalty strategy, OrbiMed provides non-dilutive structured debt capital to commercial-stage healthcare companies and monetizes royalty streams from owners of intellectual property, generating both interest/royalty income and capital appreciation.

orbimed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
Pricing details1 tier
1Private investment fund commitments with terms not publicly disclosed
ModelOtherBilling cadenceMulti-year contract
Notes

Fees, minimum commitments, and carried interest structures are negotiated bilaterally with limited partners and are not publicly listed.

orbimed.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1OrbiMed Healthcare Royalty & Credit Fund V
Description

OrbiMed's fifth dedicated royalty/credit fund, which closed at $1.86 billion and provides commercial-stage healthcare companies with non-dilutive structured debt capital and royalty monetization.

orbimed.com
Core offering1 text field

OrbiMed is a global healthcare-dedicated investment firm founded in 1989 with approximately $20 billion in assets under management, operating across three principal strategies: Private Equity (growth capital, venture, and structured investments in healthcare companies), Private Credit/Royalty (royalty financing and credit solutions for biopharma), and Public Equity (long-only and long/short public-market healthcare investing).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • OrbiMed ranks number one on the Endpoints top 100 list of biotech venture investors
+3 more records
Product overview1 text field

OrbiMed operates as a global healthcare investment firm (not a single unified software product), offering three complementary investment strategies that together span the full healthcare capital structure. The Private Equity strategy invests from seed through growth equity across biopharmaceuticals, medical devices, diagnostics, and healthcare services globally. The Private Credit / Royalty strategy provides non-dilutive structured debt and royalty monetization for commercial-stage healthcare companies, including the recently launched $1.86B Healthcare Royalty & Credit Fund V. The Public Equity strategy manages long/short event-driven funds and closed-end investment trusts across publicly-traded healthcare companies worldwide. Together these three pillars deploy approximately $20B across 500+ portfolio companies (such as Adaptive Biotechnologies, ADARx, Treeline Biosciences, and Mirador Therapeutics), supported by 150+ professionals across 12 global locations.

Product and service3 records
1OrbiMed Private Equity Strategy
CategoryPrivate Equity Fund
Description

Growth-equity, venture, and structured private investments in healthcare companies across all stages and therapeutic areas, for limited partners and underlying portfolio companies.

2OrbiMed Private Credit / Royalty Strategy
CategoryPrivate Credit / Royalty Fund
Description

Royalty monetization financing and private credit solutions extended to biopharmaceutical and healthcare companies, providing non-dilutive capital to commercial and late-stage assets.

3OrbiMed Public Equity Strategy
CategoryPublic Equity Fund
Description

Long-only and long/short public-market investments in global healthcare equities, managed for institutional limited partners.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierStrategic Incubator PartnerTypeStrategic or Co-development Partner
Description

Co-founding partner of FutuRx, an Israel-based biotech incubator, alongside OrbiMed Israel Partners and Takeda Ventures Inc., teaming with the Office of the Chief Scientist of the Ministry of Economy in a national initiative to transform breakthrough discoveries into novel medicines.

Strategic tierStrategic Incubator PartnerTypeStrategic or Co-development Partner
Description

Co-founding partner of FutuRx alongside Johnson & Johnson Innovation - JJDC and OrbiMed Israel Partners, participating in the national Israeli initiative to bridge the gap between concept and proof-of-concept for novel medicines.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Boston-based healthcare-only investment manager operating a crossover fund and dedicated venture strategy; a recurring co-investor alongside OrbiMed in dozens of biotech rounds (e.g., Immunic, Windward Bio, Terremoto, ALX Oncology, Q32 Bio) with a directly comparable sector focus and stage mix.

TypeDirect peer
Description

Healthcare-focused venture and public equities manager based in Seattle; a recurring OrbiMed co-lead in biotech rounds (e.g., AirNexis Therapeutics, Angitia, Sidewinder), with a directly comparable focus on biopharmaceutical venture creation and crossover investing.

TypeDirect peer
Description

Chicago-based, healthcare-only venture firm investing across biotech, medtech, and diagnostics from seed through public markets; competes with OrbiMed at the early-stage end of the healthcare capital structure and is a frequent co-investor in companies like Mirador Therapeutics.

4Baker Bros. Advisors
TypeDirect peer
Description

New York-based, healthcare-only specialist managing long-only equities and venture capital across biopharmaceuticals; one of the largest dedicated healthcare-only investment franchises and a direct competitor to OrbiMed across public crossover and private biotech rounds.

TypeDirect peer
Description

Healthcare-dedicated franchise of Bain Capital investing across venture, growth, and credit in biopharma and medtech; competes head-to-head with OrbiMed for life sciences deals and offers a comparable cross-strategy platform (equity plus structured credit).

TypeDirect peer
Description

New York-based healthcare investment manager providing venture, public, and structured debt capital to biopharma and medtech companies; a direct competitor to OrbiMed across the full healthcare capital structure, with similar AUM scale and a New York headquarters.

TypeDirect peer
Description

Boston-based, healthcare-only early-stage venture firm building biotech companies from inception; overlaps with OrbiMed at the seed/Series A end of healthcare (Atlas participated alongside OrbiMed in Q32 Bio) and competes for the same founder relationships.

TypeDirect peer
Description

Menlo Park-based growth equity firm dedicated to healthcare with a focus on late-stage biopharma and medtech; a recurring co-investor with OrbiMed (e.g., AirNexis Therapeutics) and a directly comparable growth-stage healthcare franchise.

TypeBroad incumbent
Description

Large, diversified global asset manager with dedicated healthcare public equity strategies; a recurring co-investor with OrbiMed in crossover and PIPE financings (Lycia, Windward Bio, Relmada) but competes only as a generalist with a healthcare specialist sleeve, not a pure-play comparable.

TypeBroad incumbent
Description

Large, multi-stage venture firm with a dedicated healthcare practice across biopharma and healthtech; an established incumbent in healthcare venture investing that overlaps with OrbiMed in growth-stage rounds but is not healthcare-only and competes from a broader sector mandate.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment843 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OrbiMed

Healthcare Investment Managementorbimed.com

OrbiMed is a privately held, healthcare-only investment firm founded in 1989 managing approximately $20 billion in AUM across private equity, public equity, and royalty/credit strategies, serving life sciences and healthcare companies globally from 12 offices.

What OrbiMed does

OrbiMed Advisors LLC is a privately held, partner-led global healthcare investment firm founded in 1989 and headquartered in New York City. The firm manages approximately $20 billion in assets under management across 500+ portfolio companies and operates through three integrated strategies: Private Equity (seed to growth across biopharmaceuticals, medical devices, diagnostics, and healthcare services), Private Credit / Royalty (non-dilutive structured debt and royalty monetization for commercial-stage companies), and Public Equity (long/short event-driven funds and closed-end trusts across publicly traded healthcare companies). The firm invests globally from 12 offices spanning New York, San Francisco, Shanghai, Hong Kong, Herzliya, and London, with 150+ scientific, medical, and investment professionals executing lead-investor positions and providing board representation and follow-on capital.

The firm's core proprietary capability is a healthcare-only investment platform combining deep scientific expertise with disciplined due diligence, formalized in an ESG-aligned Responsible Investing Policy overseen by a Director–ESG. OrbiMed is ranked number one on the Endpoints News Top 100 biotech venture investors list and has backed 130+ venture-backed IPOs, 80+ developed therapies, and 110+ life sciences startups. Notable 2026 deployments include leads or co-leads in Windward Bio ($165M), Mirador Therapeutics ($250M), Odyssey Therapeutics ($310M), and the close of the $1.86B Healthcare Royalty & Credit Fund V.

OrbiMed generates revenue primarily through recurring management fees on AUM across its private equity, public equity, and private credit/royalty funds, supplemented by carried interest on successful exits and royalty/credit investment income. Capital is raised bilaterally from institutional limited partners and deployed through direct partner-led deal sourcing. Recent management includes CEO Donnie McGrath, founders Sam Isaly, Sven Borho, and Michael B. Sheffery, and managing partners Carl Gordon and W. Carter Neild.

OrbiMed firmographics

Firmographics
Name
OrbiMed
Legal name
OrbiMed Advisors LLC
Website
https://orbimed.com
Company type
Private
Founded year
1989
Operating status
Operating
Headcount range
101–250 employees
Short description
OrbiMed is a privately held, healthcare-only investment firm founded in 1989 managing approximately $20 billion in AUM across private equity, public equity, and royalty/credit strategies, serving life sciences and healthcare companies globally from 12 offices.
Ownership category
akta.pro rank

Where OrbiMed is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices6 records

Markets served

OrbiMed business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Management Fees on Funds under Management: OrbiMed earns recurring management fees on the approximately $20 billion in assets under management across its multiple private equity, public equity, private credit/royalty, and royalty funds. This is a traditional asset-management revenue stream driven by AUM size.
  2. Investment Returns (Carried Interest / Performance Fees): As a healthcare-focused investment firm investing across the capital structure (equity, credit, and hybrid instruments) from seed-stage start-ups to large multinational corporations, OrbiMed generates returns from realized and unrealized gains on its investments, including carried interest on successful exits. Notable successes include 130+ venture-backed IPOs from its portfolio.
  3. Royalty Monetization & Structured Credit Income: Through its Private Credit/Royalty strategy, OrbiMed provides non-dilutive structured debt capital to commercial-stage healthcare companies and monetizes royalty streams from owners of intellectual property, generating both interest/royalty income and capital appreciation.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPrivate investment fund commitments with terms not publicly disclosed

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

OrbiMed product offering

Product offering

Core offering

OrbiMed is a global healthcare-dedicated investment firm founded in 1989 with approximately $20 billion in assets under management, operating across three principal strategies: Private Equity (growth capital, venture, and structured investments in healthcare companies), Private Credit/Royalty (royalty financing and credit solutions for biopharma), and Public Equity (long-only and long/short public-market healthcare investing).

Product overview

OrbiMed operates as a global healthcare investment firm (not a single unified software product), offering three complementary investment strategies that together span the full healthcare capital structure. The Private Equity strategy invests from seed through growth equity across biopharmaceuticals, medical devices, diagnostics, and healthcare services globally. The Private Credit / Royalty strategy provides non-dilutive structured debt and royalty monetization for commercial-stage healthcare companies, including the recently launched $1.86B Healthcare Royalty & Credit Fund V. The Public Equity strategy manages long/short event-driven funds and closed-end investment trusts across publicly-traded healthcare companies worldwide. Together these three pillars deploy approximately $20B across 500+ portfolio companies (such as Adaptive Biotechnologies, ADARx, Treeline Biosciences, and Mirador Therapeutics), supported by 150+ professionals across 12 global locations.

Differentiator

Problem solved

Functional benefit

Brands

  • OrbiMed Healthcare Royalty & Credit Fund V: OrbiMed's fifth dedicated royalty/credit fund, which closed at $1.86 billion and provides commercial-stage healthcare companies with non-dilutive structured debt capital and royalty monetization.

Products and services

  • OrbiMed Private Equity Strategy Growth-equity, venture, and structured private investments in healthcare companies across all stages and therapeutic areas, for limited partners and underlying portfolio companies.
  • OrbiMed Private Credit / Royalty Strategy Royalty monetization financing and private credit solutions extended to biopharmaceutical and healthcare companies, providing non-dilutive capital to commercial and late-stage assets.
  • OrbiMed Public Equity Strategy Long-only and long/short public-market investments in global healthcare equities, managed for institutional limited partners.

Quantifiable outcome

  • OrbiMed ranks number one on the Endpoints top 100 list of biotech venture investors
  • +3 more outcomes

Companies that use OrbiMed

Customer profile

Named customers6 records

Segments6 records

Ideal customer profiles2 records

OrbiMed technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

OrbiMed partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered strategic incubator partner.

  • Johnson & Johnson Innovation - JJDCstrategic incubator partnerStrategic or Co-development PartnerCo-founding partner of FutuRx, an Israel-based biotech incubator, alongside OrbiMed Israel Partners and Takeda Ventures Inc., teaming with the Office of the Chief Scientist of the Ministry of Economy in a national initiative to transform breakthrough discoveries into novel medicines.
  • Takeda Ventures Inc.strategic incubator partnerStrategic or Co-development PartnerCo-founding partner of FutuRx alongside Johnson & Johnson Innovation - JJDC and OrbiMed Israel Partners, participating in the national Israeli initiative to bridge the gap between concept and proof-of-concept for novel medicines.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

OrbiMed competitors and assessment

Company assessment

Direct peers

  • RA Capital Management: Boston-based healthcare-only investment manager operating a crossover fund and dedicated venture strategy; a recurring co-investor alongside OrbiMed in dozens of biotech rounds (e.g., Immunic, Windward Bio, Terremoto, ALX Oncology, Q32 Bio) with a directly comparable sector focus and stage mix.
  • Frazier Life Sciences: Healthcare-focused venture and public equities manager based in Seattle; a recurring OrbiMed co-lead in biotech rounds (e.g., AirNexis Therapeutics, Angitia, Sidewinder), with a directly comparable focus on biopharmaceutical venture creation and crossover investing.
  • ARCH Venture Partners: Chicago-based, healthcare-only venture firm investing across biotech, medtech, and diagnostics from seed through public markets; competes with OrbiMed at the early-stage end of the healthcare capital structure and is a frequent co-investor in companies like Mirador Therapeutics.
  • Baker Bros. Advisors: New York-based, healthcare-only specialist managing long-only equities and venture capital across biopharmaceuticals; one of the largest dedicated healthcare-only investment franchises and a direct competitor to OrbiMed across public crossover and private biotech rounds.
  • Bain Capital Life Sciences: Healthcare-dedicated franchise of Bain Capital investing across venture, growth, and credit in biopharma and medtech; competes head-to-head with OrbiMed for life sciences deals and offers a comparable cross-strategy platform (equity plus structured credit).
  • Deerfield Management: New York-based healthcare investment manager providing venture, public, and structured debt capital to biopharma and medtech companies; a direct competitor to OrbiMed across the full healthcare capital structure, with similar AUM scale and a New York headquarters.
  • Atlas Venture: Boston-based, healthcare-only early-stage venture firm building biotech companies from inception; overlaps with OrbiMed at the seed/Series A end of healthcare (Atlas participated alongside OrbiMed in Q32 Bio) and competes for the same founder relationships.
  • Longitude Capital: Menlo Park-based growth equity firm dedicated to healthcare with a focus on late-stage biopharma and medtech; a recurring co-investor with OrbiMed (e.g., AirNexis Therapeutics) and a directly comparable growth-stage healthcare franchise.

Broad incumbents

  • Janus Henderson Investors: Large, diversified global asset manager with dedicated healthcare public equity strategies; a recurring co-investor with OrbiMed in crossover and PIPE financings (Lycia, Windward Bio, Relmada) but competes only as a generalist with a healthcare specialist sleeve, not a pure-play comparable.
  • New Enterprise Associates (NEA): Large, multi-stage venture firm with a dedicated healthcare practice across biopharma and healthtech; an established incumbent in healthcare venture investing that overlaps with OrbiMed in growth-stage rounds but is not healthcare-only and competes from a broader sector mandate.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat5 records

Key risks4 records

Key highlights7 records

Customer concentration

OrbiMed social profiles

Digital presence

OrbiMed compliance and trust

Trust signal

Compliance3 records

OrbiMed financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OrbiMed leadership team

Management profile

Number of profiles

Profiles8 records

OrbiMed subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

OrbiMed funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OrbiMed M&A and investment

M&A and investment

M&A1 record

Investments843 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OrbiMed

What does OrbiMed do?

OrbiMed is a global healthcare-dedicated investment firm founded in 1989 with approximately $20 billion in assets under management, operating across three principal strategies: Private Equity (growth capital, venture, and structured investments in healthcare companies), Private Credit/Royalty (royalty financing and credit solutions for biopharma), and Public Equity (long-only and long/short public-market healthcare investing).

Is OrbiMed a public or private company?

OrbiMed is a private company. It is classified as management employee owned and is currently operating.

When was OrbiMed founded?

OrbiMed was founded in 1989. It employs 101 to 250 people.

Where is OrbiMed based?

OrbiMed is headquartered in New York, United States, in the North America region.

How does OrbiMed make money?

Three revenue lines are on record. Management Fees on Funds under Management is the primary driver. The others are investment Returns (Carried Interest / Performance Fees) and royalty Monetization & Structured Credit Income.

Who are OrbiMed's main competitors?

Direct peers on record are RA Capital Management, Frazier Life Sciences, ARCH Venture Partners, Baker Bros. Advisors, Bain Capital Life Sciences, Deerfield Management, Atlas Venture and Longitude Capital. Broad incumbents are Janus Henderson Investors and New Enterprise Associates (NEA).

Does OrbiMed have an API?

No public API is recorded for OrbiMed.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Dealroom.coMarrow debuts with $120M Series B to target blood disorders in vivo | Dealroom NewsMarrow Therapeutics raised $120 million in a Series B led by OrbiMed, with participation from RTW, KKR, and Columbia Threadneedle. The biotech will fund its bone marrow-targeted platform, with lead candidate MAR-101 preclinical for sickle cell disease and beta thalassemia. The round ranks in the 95th percentile among US health Series B rounds.STATWith $173 million, new startup takes aim at sickle cellMarrow Therapeutics was founded by Romesh Subramanian with $173 million in Series A and B funding from Scion Life Sciences, venBio, OrbiMed, and others. The startup aims to develop a treatment for sickle cell disease that is as effective as gene therapy but without its drawbacks. Subramanian said the company expects it to be as good as gene therapy in patients.FierceBiotechMarrow extracts $120M series B to advance preclinical blood disease therapyMarrow Therapeutics raised $120 million in a series B led by OrbiMed, bringing total funding to $173 million. Its lead candidate MAR-101 uses an in vivo transferrin antibody platform to reduce BCL11A, targeting sickle cell disease and beta thalassemia. The company aims to offer a more accessible alternative to gene therapies.Defense WorldElectra Therapeutics (NASDAQ:ETRA) Stock: Insider Orbimed Advisors Llc Buys 245,113 SharesOrbimed Advisors Llc bought 245,113 shares of Electra Therapeutics on November 3rd at $7.86 per share, increasing its stake by 4.97%. The company's stock opened at $7.80, and analysts have a consensus 'Buy' rating with an average price target of $33.50.American Banking and Market NewsElectra Therapeutics (NASDAQ:ETRA) Stock: Insider Orbimed Advisors Llc Buys 71,367 SharesOrbimed Advisors Llc purchased 71,367 shares of Electra Therapeutics on November 4th at $7.53 per share, increasing its stake by 1.39%. The company's stock opened at $7.80, with analysts giving an average "Buy" rating and a $33.50 price target.American Banking and Market NewsElectra Therapeutics (NASDAQ:ETRA) Stock: Insider Orbimed Advisors Llc Purchases 156,091 SharesOrbimed Advisors Llc purchased 156,091 Electra Therapeutics shares on November 5th at $7.31 each, increasing its stake by 3.08%. Analysts rate the stock a Buy with a consensus price target of $33.50.BloombergApollo-Backed Dental Firm vVardis Seeks $228.6 Million in US IPOvVardis Holding AG, a Swiss dental startup, is seeking to raise up to $228.6 million in a US IPO, offering 9.524 million shares at $21 to $24 each. The company, backed by Apollo Global Management and OrbiMed Advisors, granted underwriters the option to purchase up to 1.43 million additional shares from founders Haley and Goly Abivardi.American Banking and Market NewsAspen Neuroscience (NASDAQ:ASPE) Stock: Insider Orbimed Advisors Llc Acquires 1,000,000 SharesOrbimed Advisors Llc, a director of Aspen Neuroscience, acquired 1,000,000 shares at $15.00 each on November 2nd, spending $15,000,000. The purchase raised the director's stake by 38.62% to 3,589,132 shares, valued at approximately $53.8 million.Medical BuyerInvestors directing billions into biotech, MedTech, digital healthInvestors are directing billions into biotechnology, medical devices, and digital health, with OrbiMed raising about $3 billion in two healthcare funds in October 2026. India's bioeconomy saw $4.61 billion in disclosed investment across 200+ transactions in 2024-2025. The article highlights challenges like regulatory risks and data privacy.BioSpaceOrbiMed raises two new life sciences funds worth $3B with one aiming for AsiaOrbiMed raised over $3 billion across two new private equity funds, including $1.9 billion for U.S. and European companies and more than $1 billion for Asia. The Asia-focused fund adds to previous raises, and the company cited China's rise in licensing deal value and AI-driven biotech growth as key drivers.